Stimulation of bacterial mutagenicity by inhibitors of mammalian cell multidrug resistance.
Ferguson
L R
LR
Cancer Research Laboratory, University of Auckland Medical School, New Zealand.
Turner
P M
PM
Baguley
B C
BC
D000609:Aminoacridines / Q000494:pharmacology*; D000666:Amphotericin B / Q000494:pharmacology; D000962:Antimalarials / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002746:Chlorpromazine / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology; D004351:Drug Resistance; D004965:Estrogen Antagonists / Q000494:pharmacology; D016368:Frameshift Mutation; D009152:Mutagenicity Tests; D009153:Mutagens / Q000494:pharmacology*; D011136:Polysorbates / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D012486:Salmonella typhimurium / Q000187:drug effects*
D000609:Aminoacridines; D000962:Antimalarials; D000970:Antineoplastic Agents; D002121:Calcium Channel Blockers; D004965:Estrogen Antagonists; D009153:Mutagens; D011136:Polysorbates; C063556:3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine; D000666:Amphotericin B; D016572:Cyclosporine; D012110:Reserpine; D002746:Chlorpromazine